Reported resultsCompany-reported
What was reported
Cambridge, Mass., May 7, 2026 – Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended March 31, 2026 and provided a business update.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 7, 2026 · Open the source ↗
What the evidence supports
Prime Medicine published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlinePrime Medicine Reports First Quarter 2026 Financial Results and Provides Business UpdatesU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 7, 2026 · Open the source ↗
Press release lead paragraphCambridge, Mass., May 7, 2026 – Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended March 31, 2026 and provided a business update.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 7, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:51 UTC
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.